Abeona Therapeutics Announces Upcoming Conference Participation

NEW YORK and CLEVELAND, Sept. 22, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases, today announced the Company’s senior management team and clinical partners will participate in the following investor and industry conferences:

Cantor Fitzgerald Global Healthcare ConferenceDate: Monday, September 25th  Presentation time: 2:25 PM ET Location: New York City, NYWebcast: http://wsw.com/webcast/cantor6/abeo/

Cell & Gene Meeting on the MesaDate: October 4th-6thLocation: La Jolla, CAWebsite:  www.meetingonthemesa.com

The Jefferies 2017 Gene Therapy Summit Date: Thursday, October 12th Presentation time: 11:30 AM ETLocation: New York City, NY

The European Society of Gene and Cell Therapy (ESGCT)Date: October 17th-20thLocation: Berlin, Germany Website:  www.esgct.eu

About Abeona: Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene therapies for life-threatening rare genetic diseases. Abeona's lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).  Abeona is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona has a proprietary vector platform, AIM™, for next generation product candidates.  For more information, visit www.abeonatherapeutics.com.

Investor Contact: Christine Silverstein Vice President, Investor Relations Abeona Therapeutics Inc. +1 (212) 786-6212 [email protected]

Media Contact: Lynn Granito Berry & Company Public Relations +1 (212) 253-8881 [email protected]

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements are subject to numerous risks and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to develop our products and technologies; the ability to secure licenses for any technology that may be necessary to commercialize our products; the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic conditions; and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.

Source: Abeona Therapeutics Inc

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Abeona Therapeutics (ABEO) PT Lowered to $21 at Oppenheimer
• HawkEye 360 wins NRO contract for commercial RF data services
• ONE Nuclear Energy names CFO and nominates new board director